The Wall Street Journal reports, “AstraZeneca said it has set aside provisions of $430 million in relation to various federal and state investigations and civil lawsuits, relating to the company’s marketing and pricing practices. It said the sum represents a ‘reasonable estimate of the losses expected’ from these investigations and lawsuits.” The company “has disclosed that the various investigations and lawsuits it is facing involve a number of its drugs, including the heartburn drug Nexium and the schizophrenia drugs Seroquel.”
From the American Association for Justice news release.
